tiprankstipranks
Regeneron Pharmaceuticals (MX:REGN)
NASDAQ:REGN
Mexico Market
REGN
Regeneron
RESEARCH TOOLSreports

Regeneron (REGN) Stock Forecast & Price Target

― Followers
See the Price Targets and Ratings of:

REGN Analyst Ratings

Moderate Buy
21Ratings
Moderate Buy
15 Buy
6 Hold
0 Sell
Based on 21 analysts giving stock ratings to
Regeneron
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

REGN Stock 12 Month Forecast

Average Price Target

$14,268.04
Based on 21 Wall Street analysts offering 12 month price targets for Regeneron in the last 3 months. The average price target is $14,268.04 with a high forecast of $17,508.84 and a low forecast of $11,223.17. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10208":"$10,208","17509":"$17,509","12033.25":"$12,033.3","13858.5":"$13,858.5","15683.75":"$15,683.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17508.84197,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14268.03869679095,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11223.16770277,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10208,12033.25,13858.5,15683.75,17509],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10835.99,11349.286305384616,11862.58261076923,12375.878916153846,12889.175221538462,13402.471526923076,13915.767832307693,14429.064137692309,14942.360443076923,15455.656748461539,15968.953053846155,16482.24935923077,16995.545664615383,{"y":17508.84197,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10835.99,11099.993745906995,11363.997491813992,11628.001237720988,11892.004983627985,12156.00872953498,12420.012475441978,12684.016221348973,12948.01996725597,13212.023713162966,13476.027459069963,13740.031204976958,14004.034950883954,{"y":14268.03869679095,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10835.99,10865.772900213076,10895.555800426153,10925.338700639231,10955.121600852308,10984.904501065384,11014.687401278461,11044.47030149154,11074.253201704616,11104.036101917693,11133.81900213077,11163.601902343848,11193.384802556924,{"y":11223.16770277,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10209.371,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10541.017,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10727.315,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10955.793,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12150.973,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13751.825,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13523.441,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12475.904,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13592.558,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13099.29,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11801.252,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10450,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10835.99,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$17,509Average Price Target$14,268Lowest Price Target$11,223
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on MX:REGN
John Newman
Canaccord Genuity
Canaccord Genuity
$15,320.24
Buy
―
Reiterated
07/22/26
Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN), Celldex (NASDAQ: CLDX) and Nurix Therapeutics (NASDAQ: NRIX)
Guggenheim Analyst forecast on MX:REGN
Yatin Suneja
Guggenheim
Guggenheim
$17,421.3→$17,508.84
Buy
―
Assigned
07/21/26
Regeneron price target raised to $1,000 from $995 at GuggenheimRegeneron price target raised to $1,000 from $995 at Guggenheim
Goldman Sachs Analyst forecast on MX:REGN
Salveen Richter
Goldman Sachs
Goldman Sachs
$16,948.56→$16,896.03
Buy
―
Reiterated
07/20/26
Regeneron (REGN) Receives a Buy from Goldman Sachs
Citi Analyst forecast on MX:REGN
Geoff Meacham
Citi
Citi
$12,256.19
Hold
―
Reiterated
07/15/26
Regeneron (REGN) Gets a Hold from Citi
Bank of America Securities Analyst forecast on MX:REGN
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$15,057.6→$14,987.57
Buy
―
Reiterated
07/13/26
Regeneron: Buy Rating Reaffirmed as Analyst Trims Eylea HD Forecasts and Lowers Price Target to $856 on Pipeline-Driven Upside Potential
BMO Capital Analyst forecast on MX:REGN
Evan Seigerman
BMO Capital
BMO Capital
$12,781.45
Buy
―
Reiterated
07/13/26
Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN) and InMode (NASDAQ: INMD)
Piper Sandler Analyst forecast on MX:REGN
Biren Amin
Piper Sandler
Piper Sandler
$14,952.55
Buy
―
Assigned
07/09/26
Regeneron price target lowered to $854 from $855 at Piper SandlerRegeneron price target lowered to $854 from $855 at Piper Sandler
Wells Fargo Analyst forecast on MX:REGN
Mohit Bansal
Wells Fargo
Wells Fargo
$12,256.19
Hold
―
Assigned
07/08/26
Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN), Newron Pharmaceuticals SpA (Other OTC: NWPHF) and Boston Scientific (NYSE: BSX)
Morgan Stanley Analyst forecast on MX:REGN
Terence Flynn
Morgan Stanley
Morgan Stanley
$13,796.97→$12,781.45
Hold
―
Reiterated
07/08/26
Regeneron price target lowered to $730 from $788 at Morgan StanleyRegeneron price target lowered to $730 from $788 at Morgan Stanley
Truist Financial Analyst forecast on MX:REGN
Gregory Renza
Truist Financial
Truist Financial
$13,621.88→$13,464.3
Buy
―
Reiterated
07/07/26
Regeneron price target lowered to $769 from $778 at TruistRegeneron price target lowered to $769 from $778 at Truist
RBC Capital Analyst forecast on MX:REGN
Brian Abrahams
RBC Capital
RBC Capital
$12,378.75→$12,186.15
Hold
―
Reiterated
07/07/26
Regeneron price target lowered to $696 from $707 at RBC CapitalRegeneron price target lowered to $696 from $707 at RBC Capital
HSBC Analyst forecast on MX:REGN
Rajesh Kumar
HSBC
HSBC
$17,333.75→$14,007.07
Buy
―
Reiterated
07/06/26
Regeneron price target lowered to $800 from $990 at HSBCRegeneron price target lowered to $800 from $990 at HSBC
Cantor Fitzgerald Analyst forecast on MX:REGN
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
$13,744.44→$13,131.63
Buy
―
Reiterated
07/06/26
Regeneron price target lowered to $750 from $785 at Cantor FitzgeraldRegeneron price target lowered to $750 from $785 at Cantor Fitzgerald
Scotiabank Analyst forecast on MX:REGN
Louise Chen
Scotiabank
Scotiabank
$13,481.81
Hold
―
Reiterated
07/01/26
Analysts Conflicted on These Healthcare Names: Alumis Inc. (NASDAQ: ALMS), Glaukos (NYSE: GKOS) and Regeneron (NASDAQ: REGN)
Leerink Partners Analyst forecast on MX:REGN
David Risinger
Leerink Partners
Leerink Partners
$13,867→$11,223.17
Hold
―
Downgraded
05/18/26
Regeneron downgraded to Market Perform from Outperform at LeerinkRegeneron downgraded to Market Perform from Outperform at Leerink
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on MX:REGN
John Newman
Canaccord Genuity
Canaccord Genuity
$15,320.24
Buy
―
Reiterated
07/22/26
Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN), Celldex (NASDAQ: CLDX) and Nurix Therapeutics (NASDAQ: NRIX)
Guggenheim Analyst forecast on MX:REGN
Yatin Suneja
Guggenheim
Guggenheim
$17,421.3→$17,508.84
Buy
―
Assigned
07/21/26
Regeneron price target raised to $1,000 from $995 at GuggenheimRegeneron price target raised to $1,000 from $995 at Guggenheim
Goldman Sachs Analyst forecast on MX:REGN
Salveen Richter
Goldman Sachs
Goldman Sachs
$16,948.56→$16,896.03
Buy
―
Reiterated
07/20/26
Regeneron (REGN) Receives a Buy from Goldman Sachs
Citi Analyst forecast on MX:REGN
Geoff Meacham
Citi
Citi
$12,256.19
Hold
―
Reiterated
07/15/26
Regeneron (REGN) Gets a Hold from Citi
Bank of America Securities Analyst forecast on MX:REGN
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$15,057.6→$14,987.57
Buy
―
Reiterated
07/13/26
Regeneron: Buy Rating Reaffirmed as Analyst Trims Eylea HD Forecasts and Lowers Price Target to $856 on Pipeline-Driven Upside Potential
BMO Capital Analyst forecast on MX:REGN
Evan Seigerman
BMO Capital
BMO Capital
$12,781.45
Buy
―
Reiterated
07/13/26
Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN) and InMode (NASDAQ: INMD)
Piper Sandler Analyst forecast on MX:REGN
Biren Amin
Piper Sandler
Piper Sandler
$14,952.55
Buy
―
Assigned
07/09/26
Regeneron price target lowered to $854 from $855 at Piper SandlerRegeneron price target lowered to $854 from $855 at Piper Sandler
Wells Fargo Analyst forecast on MX:REGN
Mohit Bansal
Wells Fargo
Wells Fargo
$12,256.19
Hold
―
Assigned
07/08/26
Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN), Newron Pharmaceuticals SpA (Other OTC: NWPHF) and Boston Scientific (NYSE: BSX)
Morgan Stanley Analyst forecast on MX:REGN
Terence Flynn
Morgan Stanley
Morgan Stanley
$13,796.97→$12,781.45
Hold
―
Reiterated
07/08/26
Regeneron price target lowered to $730 from $788 at Morgan StanleyRegeneron price target lowered to $730 from $788 at Morgan Stanley
Truist Financial Analyst forecast on MX:REGN
Gregory Renza
Truist Financial
Truist Financial
$13,621.88→$13,464.3
Buy
―
Reiterated
07/07/26
Regeneron price target lowered to $769 from $778 at TruistRegeneron price target lowered to $769 from $778 at Truist
RBC Capital Analyst forecast on MX:REGN
Brian Abrahams
RBC Capital
RBC Capital
$12,378.75→$12,186.15
Hold
―
Reiterated
07/07/26
Regeneron price target lowered to $696 from $707 at RBC CapitalRegeneron price target lowered to $696 from $707 at RBC Capital
HSBC Analyst forecast on MX:REGN
Rajesh Kumar
HSBC
HSBC
$17,333.75→$14,007.07
Buy
―
Reiterated
07/06/26
Regeneron price target lowered to $800 from $990 at HSBCRegeneron price target lowered to $800 from $990 at HSBC
Cantor Fitzgerald Analyst forecast on MX:REGN
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
$13,744.44→$13,131.63
Buy
―
Reiterated
07/06/26
Regeneron price target lowered to $750 from $785 at Cantor FitzgeraldRegeneron price target lowered to $750 from $785 at Cantor Fitzgerald
Scotiabank Analyst forecast on MX:REGN
Louise Chen
Scotiabank
Scotiabank
$13,481.81
Hold
―
Reiterated
07/01/26
Analysts Conflicted on These Healthcare Names: Alumis Inc. (NASDAQ: ALMS), Glaukos (NYSE: GKOS) and Regeneron (NASDAQ: REGN)
Leerink Partners Analyst forecast on MX:REGN
David Risinger
Leerink Partners
Leerink Partners
$13,867→$11,223.17
Hold
―
Downgraded
05/18/26
Regeneron downgraded to Market Perform from Outperform at LeerinkRegeneron downgraded to Market Perform from Outperform at Leerink
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AORTArtivion
ENOVEnovis
GKOSGlaukos
IFRXInflaRx
BKDBrookdale Senior Living
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Regeneron

3 Months
William PickeringBernstein
Success Rate
10/16 ratings generated profit
63%
Average Return
+3.19%
Copying William Pickering's trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +3.19% per trade.
1 Year
Evan SeigermanBMO Capital
Success Rate
31/41 ratings generated profit
76%
Average Return
+9.25%
Copying Evan Seigerman's trades and holding each position for 1 Year would result in 75.61% of your transactions generating a profit, with an average return of +9.25% per trade.
2 Years
Evan SeigermanBMO Capital
Success Rate
21/41 ratings generated profit
51%
Average Return
+7.54%
Copying Evan Seigerman's trades and holding each position for 2 Years would result in 51.22% of your transactions generating a profit, with an average return of +7.54% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

REGN Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
1
1
1
Buy
41
44
47
41
27
Hold
15
17
17
15
12
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
56
61
65
57
40
In the current month, REGN has received 28 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. REGN average Analyst price target in the past 3 months is 14,268.04.
Each month's total comprises the sum of three months' worth of ratings.

REGN Financial Forecast

REGN Earnings Forecast

Next quarter’s earnings estimate for REGN is $178.82 with a range of $133.77 to $215.88. The previous quarter’s EPS was $165.81. REGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year REGN has Performed in-line its overall industry.
Next quarter’s earnings estimate for REGN is $178.82 with a range of $133.77 to $215.88. The previous quarter’s EPS was $165.81. REGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year REGN has Performed in-line its overall industry.

REGN Sales Forecast

Next quarter’s sales forecast for REGN is $66.82B with a range of $62.05B to $73.26B. The previous quarter’s sales results were $63.13B. REGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year REGN has Performed in-line its overall industry.
Next quarter’s sales forecast for REGN is $66.82B with a range of $62.05B to $73.26B. The previous quarter’s sales results were $63.13B. REGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year REGN has Performed in-line its overall industry.

REGN Stock Forecast FAQ

What is MX:REGN’s average 12-month price target, according to analysts?
Based on analyst ratings, Regeneron Pharmaceuticals’s 12-month average price target is 14,268.04.
    What is MX:REGN’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for MX:REGN, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Regeneron Pharmaceuticals a Buy, Sell or Hold?
        Regeneron Pharmaceuticals has a consensus rating of Moderate Buy, which is based on 15 buy ratings, 6 hold ratings and 0 sell ratings.
          What is Regeneron Pharmaceuticals’s share price target?
          The average share price target for Regeneron Pharmaceuticals is 14,268.04. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $17,508.84 ,and the lowest forecast is $11,223.17. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Regeneron Pharmaceuticals?
            Regeneron Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.
              How can I buy shares of Regeneron Pharmaceuticals?
              To buy shares of MX:REGN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.